LifePlus has introduced what it claims to be the world’s first non-invasive continuous blood glucose monitoring multi-sensor wearable device.
The multi-sensor device, dubbed Lifeleaf, non-invasively monitors heart rate, blood pressure, respiration rate and oxygen saturation.
The wearable smartwatch can continuously and non-invasively monitor and tract major chronic health risks like diabetes, cardiac arrhythmia, congestive heart failure, COPD, sleep apnea and hypertension.
It is based on an open standards based-software stack that is also available to license. LifePlus also announced that LifeLeaf is presently active in five trials across the world.
Lifeleaf, which will be available later this year, is a cloud-based AI solution with a user-interface that the company says is easy to use, as well as a connected mobile app that offers cloud-based analytics with real-time notifications.
LifePlus is being supported by Silicon Valley-based JLA Advisors along with John Trobough serving as the executive chairman of the board.
The product was announced as the Medical Wearables Conference in Santa Clara, California.
Trobough said: “We have been in stealth mode and today we are thrilled to announce the introduction of LifeLeaf as part of the burgeoning medical wearables category.
“Managing diabetes and other chronic diseases requires early and timely detection, rapid intervention and high compliance. LifeLeaf exceeds those requirements with its patent-pending open standards-based software stack and cloud-based analytics.
“LifeLeaf is different from any other product and software technology available – it is truly unique and we are excited to make this multi-sensor capability available to companies and developers globally.”